Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 271-571-3 | CAS number: 68585-64-8
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Skin sensitisation
Administrative data
- Endpoint:
- skin sensitisation: in vivo (LLNA)
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- 20 Feb - 28 Mar 2018
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- guideline study
- Justification for type of information:
- The study was conducted within the scope of global registration outside the European Union and outside REACH.
Data source
Reference
- Reference Type:
- study report
- Title:
- Unnamed
- Year:
- 2 018
- Report date:
- 2018
Materials and methods
Test guidelineopen allclose all
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 442B (Skin Sensitization: Local Lymph Node Assay: BrdU-ELISA)
- Version / remarks:
- adopted in 2010
- Deviations:
- yes
- Remarks:
- no data on cellular proliferation provided (BrdU incorporation)
- Qualifier:
- according to guideline
- Guideline:
- EPA OPPTS 870.2600 (Skin Sensitisation)
- GLP compliance:
- yes
- Type of study:
- mouse local lymph node assay (LLNA): BrdU-ELISA
Test material
- Reference substance name:
- Dihydrogen bis[P,P-dioctyl diphosphato(2-)-O'',O''''][hydroxyacetato(2-)-O1,O2]titanate(2-), branched and linear
- EC Number:
- 271-571-3
- EC Name:
- Dihydrogen bis[P,P-dioctyl diphosphato(2-)-O'',O''''][hydroxyacetato(2-)-O1,O2]titanate(2-), branched and linear
- Cas Number:
- 68585-64-8
- Molecular formula:
- not applicable (UVCB substance)
- IUPAC Name:
- ({bis[(2-ethylhexyl)oxy]phosphoryl}oxy)[(2-{[({bis[(2-ethylhexyl)oxy]phosphoryl}oxy)(hydroxy)phosphoryl]oxy}-4-oxo-1,3-dioxa-2-titanacyclopentan-2-yl)oxy]phosphinic acid; {[({bis[(2-ethylhexyl)oxy]phosphanyl}oxy)({[({bis[(2-ethylhexyl)oxy]phosphoryl}oxy)(hydroxy)phosphoryl]oxy})[(2-hydroxyacetyl)oxy]titanio]oxy}({bis[(2-ethylhexyl)oxy]phosphoryl}oxy)phosphinic acid
Constituent 1
In vivo test system
Test animals
- Species:
- mouse
- Strain:
- CBA:J
- Sex:
- female
- Details on test animals and environmental conditions:
- TEST ANIMALS
- Source: Jackson Laboratories (Bar Harbor, Maine, USA)
- Females nulliparous and non-pregnant: yes
- Weight at study initiation: 18.2 – 25.3 g
- Housing: individually in suspended wire-bottom cages
- Diet: PMI Rodent Chow Diet No. 5001, ad libitum
- Water: ad libitum
- Acclimation period: at least five days
- Indication of any skin lesions: no
ENVIRONMENTAL CONDITIONS
- Temperature and humidity were continuously monitored, no further details were provided
- Photoperiod (hrs dark / hrs light): 12/12
Study design: in vivo (LLNA)
- Vehicle:
- other: Dimethylacetamide:Acetone:Ethanol 4:3:3; DaAE
- Concentration:
- Preliminary dermal irritation screen: not performed
Main study: 5, 10 and 25% (v/v) - No. of animals per dose:
- 5
- Details on study design:
- PRE-SCREEN TESTS:
- Compound solubility: The test item was found to be soluble in dimethylacetamide:acetone:ethanol 4:3:3 (DaAE) at 25%
- an in vivo pre-screen test was not performed
MAIN STUDY
Based on the results of other related test items tested in the study, test item concentrations of 5, 10 and 25% (v/v) were chosen for the main study.
ANIMAL ASSIGNMENT AND TREATMENT
- Name of test method: Local lymph node assay BrdU ELISA
- Criteria used to consider a positive response: The test item is considered to have a positive response if treatment results in a 1.6-fold or greater increase in the mean LNC proliferation (BrdU ELISA OD values) relative to that obtained for the vehicle control. Therefore, the test substance was considered as sensitizer if a SI value of 1.6 or more was achieved.
TREATMENT PREPARATION AND ADMINISTRATION:
Test formulations were prepared fresh for each day of dosing. 250 μl of the test item were added to 750 μl of DaAE and mixed to yield a 25% (v/v) formulation. 100 μl of the test item were added to 900 μl of DaAE and mixed to yield a 10% (v/v) formulation. 50 μl of the test item were added to 950 μl of DaAE and mixed to yield a 5% (v/v) formulation.
The test item at concentrations of 5, 10 and 25% (v/v) in DaAE was topically applied to the dorsum of each ear once daily for three consecutive days. The test item was spread over the entire dorsal surface of each ear using a micropipette to deliver 25 µL/ear. Both ears were observed daily for erythema and scored. On Days 1, 3 and 6 ear thickness measurements were performed. On Day 5 of the main test approximately 96 h following the initial dose and 24 h prior to euthanasia, 500 µL of a 10 mg/mL concentrated BrdU solution in Dulbecco’s phosphate-buffered saline (DPBS) was intraperitoneally injected into the mice. On Day 6, each mouse was euthanized using CO2 asphyxiation, and the jugular vein was opened for complete exsanguination. Gross observations of the auricular lymph nodes were made and the lymph nodes were collected. The auricular lymph nodes were combined for each animal and single-cell suspensions were prepared in RPMI-10 medium for individual animals. BrdU incorporation was detected with a BrdU-specific Enzyme-linked Immunosorbent Assay (ELISA) kit. An aliquot of 100 µL of the lymph node cell (LNC) suspension preparation was added to the wells of a flat-bottom microplate in triplicate. After fixation and denaturation of the LNC, anti-BrdU antibody was added to each well and allowed to bind. Excess unbound anti-BrdU antibody solution was then removed by washing and the substrate solution was added and allowed to generate chromogen. The absorbance of each well was measured using a MicroQuant plate reader (Bio-Tek Instruments) at 370 nm with a reference wavelength of 492 nm.
CLINICAL SIGNS
Animals were observed once daily throughout the study for clinical signs, for local irritation at the application site and for mortality.
BODY WEIGHT
The body weight of each mouse was recorded on Day 1 immediately prior to dosing, and on Day 6 prior to euthanasia.
DETAILS ON STIMULATION INDEX CALCULATION
Calculation of the Stimulation Index (SI) per animal:
SI = Mean OD test article / Mean OD vehicle
Calculation of the EC1.6:
EC1.6 = c + (1.6-d) / (b-d) x (a-c)
a: test article concentration at SI value “b”
b: SI value nearest to but greater than 1.6
c: test article concentration at SI value “d”
d: SI value nearest to but less than 1.6
When no treatment produces an SI value less than 1.6, the concentration at which SI = 1.6 (EC1.6) was estimated from the lowest positive (SI ≥ 1.6) test article concentration and the vehicle (i.e. 0% test article) according to the following formular:
EC1.6 = c + (1.6-d) / (b-d) x (a-c)
a: test article concentration at SI value “b”
b: SI value nearest to but greater than 1.6
c: 0% test article (vehicle only) i.e. concentration at SI value “d”
d: SI value of vehicle control = 1.0
Treatment with test item at 5% and 10% produced an SI value of exactly 1.6. However, the lower concentration takes precedence in such cases; therefore, the EC1.6 value is 5%. - Positive control substance(s):
- hexyl cinnamic aldehyde (CAS No 101-86-0)
- Statistics:
- For each dose group, the individual animal SI values along with the mean group SI and standard deviation were calculated, and ANOVA followed by the Student-Newman-Keuls test was performed to statistically compare each test article dose group to the vehicle control group. Although specified in the test guidelines, these calculations and results were not incorporated into the interpretation of the data. An SI value of 1.6 or more is the sole determinant for a positive sensitization response.
Results and discussion
- Positive control results:
- A 25% solution of HCA (v/v) in dimethylacetamide : acetone : ethanol (4:3:3) yielded a SI value of 3.4 ± 0.7. The 25% HCA positive control produced no more than very slight erythema. Ear thickness on Day 6 increased greater than 25% and enlargement of the lymph nodes were observed, which is consistent with historical results reported in the literature.
In vivo (LLNA)
Resultsopen allclose all
- Key result
- Parameter:
- SI
- Value:
- 1.6
- Variability:
- ± 0.7
- Test group / Remarks:
- 5% (v/v)
- Key result
- Parameter:
- SI
- Value:
- 1.6
- Variability:
- ± 0.4
- Test group / Remarks:
- 10% (v/v)
- Key result
- Parameter:
- SI
- Value:
- 2.3
- Variability:
- ± 0.8
- Test group / Remarks:
- 25% (v(v)
- Parameter:
- SI
- Value:
- 1
- Variability:
- ± 0.5
- Test group / Remarks:
- Vehicle control
- Parameter:
- SI
- Value:
- 3.4
- Variability:
- ± 0.7
- Test group / Remarks:
- Positive control
- Key result
- Parameter:
- other: EC 1.6
- Value:
- 5
- Cellular proliferation data / Observations:
- CLINICAL OBSERVATIONS:
No mortality or signs of systemic toxicity were not observed in the treatment groups or in the control groups.
ERYTHEMA AND EAR THICKNESS: Erythema was observed at all test substance concentrations (refer to Table 1). A greater than 25% increase in ear thickness on Day 6 was not measured in animals treated with the test substance (refer to Table 2).
BODY WEIGHTS:
Body weight losses were noted but were not considered significant (less than 2 grams)
Any other information on results incl. tables
Table 1: Ear thickness (Mean over 5 animals)
Mean Ear Thickness (mm) | Change (%) | ||||
Treatment | Pre- dosing (Day 1) | 48 Hr (Day 3) | End In-Life (Day 6) | Day 3 – Day 1 | Day 6 – Day 1 |
DaAE (Vehicle Control) | 0.19 | 0.19 | 0.19 | 0.00% | 0.00% |
25% HCA (Positive Control) | 0.18 | 0.23 | 0.25 | 27.8%a | 38.9%a |
5% (v/v) |
0.19 | 0.19 | 0.21 |
0.00% |
10.50% |
10% (v/v) |
0.19 |
0.20 |
0.27 |
5.30% |
42.10%a |
25% (v/v) |
0.19 |
0.22 |
0.38 |
15.80% |
100.00%a |
DaAE: Dimethylacetamide:Acetone:Ethanol 4:3:3, solvent control
HCA: hexyl cinnamic aldehyde, positive control
a = an increase in ear thickness of 25% or more indicates a more-than-moderate dermal irritation response
Table 2: Erythema score
Treatment | Animal I.D | Day 1 | Day 2 | Day 3 | Day 4 | Day 5 | Day 6 | ||||||
Left Ear | Right Ear | Left Ear | Right Ear | Left Ear | Right Ear | Left Ear | Right Ear | Left Ear | Right Ear | Left Ear | Right Ear | ||
DaAE (Vehicle Control) | 19 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
20 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
21 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
22 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
23 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
Mean | 0 | 0 | 0 | 0 | 0 | 0 | |||||||
25% HCA (Positive Control) | 24 | 0 | 0 | 1 | 0 | 2 | 1 | 1 | 1 | 1 | 1 | 0 | 1 |
25 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 1 | |
26 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | |
27 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 0 | |
28 | 0 | 0 | 1 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 1 | |
Mean | 0 | 0.3 | 1.1 | 1 | 1 | 0.5 | |||||||
5% (v/v) | 74 | 0 | 0 | 0 | 0 | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 0 |
75 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
76 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
77 | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 0 | 1 | 1 | 1 | 0 | |
78 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 1 | |
Mean | 0 | 0 | 0.4 | 0.1 | 0.1 | 0.1 | |||||||
10% (v/v) | 79 | 0 | 0 | 0 | 0 | 1 |
1 |
1 | 1 | 1 | 1 | 0 | 1 |
80 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 2 | 1 | 2 |
|
81 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 2 | 2 | 1 | 1 | |
82 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 0 | 1 | 0 | |
83 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | |
Mean | 0 | 0 | 1.0 | 0.9 | 1.3 |
1.0 |
|||||||
25% (v/v) |
84 |
0 |
0 |
1 |
0 |
2 |
2 |
2 |
2 |
2 |
2 |
2 |
2 |
85 |
0 |
0 |
0 |
0 |
1 |
1 |
2 |
2 |
2 |
3 |
2 |
2 |
|
86 |
0 |
0 |
0 |
1 |
1 |
2 |
1 |
1 |
3 |
3 |
2 |
3 |
|
87 |
0 |
0 |
1 |
0 |
1 |
1 |
1 |
1 |
2 |
2 |
2 |
2 |
|
88 |
0 |
0 |
1 |
0 |
2 |
1 |
2 |
2 |
2 |
2 |
2 |
2 |
|
Mean |
0 |
0.4 |
1.4 |
1.6 |
2.3 |
2.1 |
DaAE: Dimethylacetamide:Acetone:Ethanol 4:3:3, solvent control
HCA: hexyl cinnamic aldehyde, positive control
0 = No erythema
1 = Very slight erythema (barely perceptible)
2 = Well-defined erythema
3 = Moderate to severe erythema
Table 3: Results Stimulation Index
Treatment | Animal | Optical Density | Mean OD | SI | ||
OD1 | OD 2 | OD 3 | ||||
DaAE vehicle | 19 | 0.04 | 0.037 | 0.047 | 0.041 | 0.3 |
20 | 0.108 | 0.094 | 0.112 | 0.105 | 0.8 | |
21 | 0.201 | 0.212 | 0.17 | 0.194 | 1.5 | |
22 | 0.112 | 0.111 | 0.15 | 0.124 | 1 | |
23 | 0.215 | 0.142 | 0.19 | 0.182 | 1.4 | |
Mean | 0.129 | 1 | ||||
StDev | 0.062 | 0.5 | ||||
25% HCA pos. Control | 24 | 0.433 | 0.539 | 0.451 | 0.474 | 3.7 |
25 | 0.506 | 0.521 | 0.478 | 0.502 | 3.9 | |
26 | 0.473 | 0.528 | 0.609 | 0.537 | 4.1 | |
27 | 0.397 | 0.345 | 0.354 | 0.365 | 2.8 | |
28 | 0.339 | 0.375 | 0.266 | 0.327 | 2.5 | |
Mean | 0.441 | 3.4a | ||||
StDev | 0.09 | 0.7 | ||||
5% (v/v) | 74 | 0.223 | 0.135 | 0.167 | 0.175 | 1.3 |
75 | 0.279 | 0.180 | 0.187 | 0.215 | 1.7 | |
76 | 0.247 |
0.241 |
0.297 |
0.261 |
1.9 |
|
77 |
0.372 |
0.250 |
0.275 |
0.299 |
2.3 |
|
78 |
0.094 |
0.084 |
0.035 |
0.071 |
0.5 |
|
Mean |
|
|
|
0.204 |
1.6a |
|
StDev |
|
|
|
0.088 |
0.7 |
|
10% (v/v) |
79 |
0.155 |
0.186 |
0.183 |
0.174 |
1.3 |
80 |
0.168 |
0.137 |
0.112 |
0.139 |
1 .1 |
|
81 |
0.188 |
0.203 |
0.234 |
0.208 |
1.6 |
|
82 |
0.310 |
0.260 |
0.285 |
0.285 |
2.2 |
|
83 |
0.189 |
0.258 |
0.182 |
0.209 |
1.6 |
|
Mean |
|
|
|
0.203 |
1.6a |
|
StDev |
|
|
|
0.054 |
0.4 |
|
25% (v/v) |
84 |
0.234 |
0.235 |
0.266 |
0.245 |
1.9 |
85 |
0.365 |
0.343 |
0.368 |
0.358 |
2.8 |
|
86 |
0.427 |
0.516 |
0.407 |
0.450 |
3.5 |
|
87 |
0.256 |
0.185 |
0.261 |
0.234 |
1.8 |
|
88 |
0.186 |
0.221 |
0.206 |
0.204 |
1.6 |
|
Mean |
|
|
|
0.298 |
2.3a |
|
StDev |
|
|
|
0.103 |
0.8 |
a = SI of 1.6 or more indicates a sensitizing response
DaAE: Dimethylacetamide:Acetone:Ethanol 4:3:3, solvent control
HCA: hexyl cinnamic aldehyde, positive control
Applicant's summary and conclusion
- Interpretation of results:
- other: Skin Sens. 1 (H317) according to Regulation (EC) No. 1272/2008
- Conclusions:
- CLP: Skin Sens. 1
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.